Evidence map›Paper›PMID 41167763›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Non-invasive evaluation and prediction of portal hypertension: focusing on disease progression and outcome].

P S Xu, M C Wang, J J Chen, H Y Wang

Registry-linked trialAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07521332 (Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07521332 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis: A Randomized Single-Blind Placebo-Controlled Trial at AIMS, Hyderabad, Pakistan

TypeinterventionalSponsorAsian Institute Of Medical SciencesRan2026 to 2028Enrolled220ConditionsCirrhosis, Esophageal and Gastric Varices, Ascites, Hepatic EncephalopathyArmsApixaban, Carvedilol, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

P S XuHepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
M C WangHepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J J ChenHepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China Department of Hepatology, Zengcheng Branch of Nanfang Hospital, Southern Medical University, Guangzhou 511300, China.
H Y WangHepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

Funding

National Natural Science Foundation of China 82370614, 82070650, 8220067National Postdoctoral Program for Innovative Talents of China BX20220144
6 · The paper itself

Abstract

Portal hypertension is a major complication of cirrhosis. The current gold standard for diagnosis is the hepatic venous pressure gradient, but it possesses limitations such as invasiveness. In recent years, non-invasive tests have made significant progress in terms of evaluating and prognostication of portal hypertension. This article reviews the diagnostic value and related research advancements of different non-invasive tests in assessing portal hypertension in patients with cirrhosis.

Indexed as

Hypertension, PortalLiver CirrhosisDisease ProgressionHumansPrognosis

Identifiers

PMID41167763
PMCPMC12861811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.